1.0 Trade receivable 16,579 4.7% 16,173 4.4% Net debt to EBITDA (times) 0.7 0.8 0.8 Inventories 2,372 0.7% 3,189 0.9% Net debt & lease liability & spectrum license payable to EBITDA 2.3 2.2 2.3 Others
Inventories 2,104 0.6% 3,831 1.1% Net debt & lease liability & Spectrum license payable to EBITDA 2.2 2.2 2.1 Others 4,111 1.2% 4,391 1.2% Current Assets 35,566 10% 41,017 12% Current Ratio (times) 0.4 0.4 0.4
receivables accounted 79.2% of total revenues in 2017. The revenues from collection of purchased account receivables is expected to grow further this year due to the number of fully amortized bad debt portfolio
569.79 46.4% 558.38 40.7% (11.41) (2.0%) Non-Current asset 325.20 26.5% 419.12 30.8% 93.92 28.9% Total Assets 1,226.79 100.0% 1,372.78 100.0% 145.99 11.9% Liabilities Current liability 77.35 6.3% 118.33
%) Right to use assets - - 131.79 8.7% 131.79 - Non-Current asset 419.12 30.5% 426.50 28.0% 7.38 1.8% Total Assets 1,372.78 100.0% 1,520.95 100.0% 148.17 10.8% Liabilities Current liability 118.33 8.6
1,226.79 100.0% 1,334.75 100.0% 107.96 8.8% Liabilities Current liability 77.35 6.3% 110.83 8.3% 33.48 43.3% Non-Current liability 29.96 2.4% 57.90 4.3% 27.94 93.3% Total liabilities 107.31 8.7% 168.73 12.6
impairment loss from the liquidation of Solvay Biochemicals (Taixing) Limited (“SBT”) were fully booked in 2017. * Note Please find further information in the consolidated financial statements. 2 Summary of
the liquidation of Solvay Biochemicals (Taixing) Limited were fully booked in 2017. 4. 93 MB loss on dilution on investment in an associate was recorded from the change in the Company’s ownership
. Government spending and government investment did not drive the economy fully. Meanwhile, the investment of private sector was slowed down, household sectors from various sectors paid more attention on